TD-0903 for ALI Associated With COVID-19

NCT04402866 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

235

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Lung Injury (ALI) Associated With COVID-19
Lung Inflammation Associated With COVID-19

Interventions

DRUG: TD-0903
DRUG: Placebo

Sponsor

Theravance Biopharma